ClinicalTrials.gg
CompletedNCT01119768Updated Sep 28, 2012Results posted

Esomeprazole Treatment Co-diagnosed Non Erosive Reflux Disease (NERD) and Chronic Gastritis Patients

A Phase 4 interventional study of Esomeprazole and Esomeprazole in Non Erosive Reflux Disease and Chronic Gastritis, sponsored by AstraZeneca. Completed at 8 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-09-28.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
305
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

To compare the symptom control rate between 8 weeks esomeprazole treatment regimen group and 2 weeks esomeprazole treatment regimen group in co-diagnosed NERD and chronic gastritis patients, as evaluated by GerdQ after 24 weeks maintenance treatment/follow up.

Read the detailed description

A multicenter, randomized, open-label Phase IV study exploring symptom control rate in co-diagnosed NERD and chronic gastritis patients treated with 8 weeks esomeprazole treatment regimen and 2 weeks esomeprazole treatment regimen.

02

Conditions studied

  • Non Erosive Reflux Disease
  • Chronic Gastritis

Keywords

  • GI
  • Nexium
  • Phase IV
  • Co-diagnosed NERD
03

In context

Non-Erosive Reflux Disease

47 studies on the registry are indexed under Non-Erosive Reflux Disease; 8 are open to participants now.

This study's enrollment of 305 is above the median of 160 across 34 interventional studies indexed under Non-Erosive Reflux Disease.

Browse Non-Erosive Reflux Disease studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Heartburn and/or regurgitation symptoms last for at least 3 months
  • Endoscopic diagnosed as chronic gastritis (non-atrophic, and mild atrophic gastritis) within 2 weeks prior to randomization GerdQ score =8

Exclusion criteria

Exclusion Criteria:

  • Endoscopic visible reflux esophagitis, esophageal varices, Barrett's esophagus, or peptic ulcer Patients with Hp positive result and are eager to take Hp eradication therapy will be excluded
  • If Hp positive, patients could take Hp eradication therapy after the study completion Previous PPI or H2RA therapy in the last 2 weeks before enrollment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
305 participants (actual)

Study arms

  • Active comparator
    Esomeprazole 8 weeks treatment

    20 mg q.d. (quaque die) once a day dosing for 8 weeks

    Drug: Esomeprazole

  • Active comparator
    Esomeprazole 2 Weeks Treatment

    20 mg q.d. (quaque die) once a day dosing for 2 weeks

    Drug: Esomeprazole

Interventions

  • 20mg Esomeprazole once daily, 8 weeks and 24 weeks on-demand treatment

  • 20mg Esomeprazole once daily, 2 weeks and 24 weeks follow up

06

What researchers measure

Primary outcomes

  1. Symptom Control Rate at 24 Weeks Assessed by Gerd Q Questionnaire.

    GerdQ Scores ranging from 0 to 3 were applied for the positive predictors and from 3 to 0 (reversed order, where 3 = none) for negative predictors. The GerdQ score was calculated as the sum of these scores, giving a total score ranging from 0 to 18. When GerdQ ≥8, the patients could be symptom based diagnosed as GERD. GerdQ was consisted of 3 categories: A, B and C. Each category has two questions with sum of score ranging from 0 to 6. Symptom controlled was defined as patients with all items ≤1 in A and C category of GerdQ.

    Time frame: 24 weeks

Secondary outcomes

  1. The Success Rate in Whole Study Duration.

    Success is defined as patients with symptom relief after 8 weeks or 2 weeks esomeprazole treatment, and also get symptom controlled during maintenance treatment / follow-up period.

    Time frame: 24 weeks after end of treatment

  2. Time to First Relapse.

    Time to first relapse is from the last dose during the treatment period to date of first time patient comes to the investigator due to symptom recure and need for treatment. Time to first relapse is actually the time when 50% of patients had relapse. Up to the end of study, there were less than 50% of the patients in arm esomeprazole 2 weeks group had relapse so was unable to compute this endpoint

    Time frame: From baseline to 24 weeks after end of treatment

  3. Symptom Relief Rate in 2 Treatment Regimens.

    Symptom relief is defined as no more than 1 day of mild symptoms of GERD during previous 7 days after 8 weeks or 2 weeks of treatment.

    Time frame: 8 weeks for arm 1, 2 weeks for arm 2

  4. Symptom Relief Rate After 2 Weeks and 8 Weeks in 8 Weeks Treatment Group.

    Symptom relief is defined as no more than 1 day of mild symptoms of GERD during previous 7 days after 8 weeks or 2 weeks of treatment.

    Time frame: 2 and 8 weeks

  5. Number of Patients With Unscheduled Hospital Visit(s)

    Time frame: from baseline to week 24 after end of treatment

  6. Percentage of Patients Satisfaction

    Satisfied - satisfaction score of 1-4 while very satisfied - satisfaction score of 1-2.

    Time frame: 24 weeks after end of treatment

  7. Symptom Control Rate at 8 Weeks Assessed by Gerd Q Questionnaire

    GerdQ Scores ranging from 0 to 3 were applied for the positive predictors and from 3 to 0 (reversed order, where 3 = none) for negative predictors. The GerdQ score was calculated as the sum of these scores, giving a total score ranging from 0 to 18. When GerdQ ≥8, the patients could be symptom based diagnosed as GERD. GerdQ was consisted of 3 categories: A, B and C. Each category has two questions with sum of score ranging from 0 to 6. Symptom controlled was defined as patients with all items ≤1 in A and C category of GerdQ.

    Time frame: 8 weeks

  8. Symptom Control Rate at 16 Weeks Assessed by Gerd Q Questionnaire

    GerdQ Scores ranging from 0 to 3 were applied for the positive predictors and from 3 to 0 (reversed order, where 3 = none) for negative predictors. The GerdQ score was calculated as the sum of these scores, giving a total score ranging from 0 to 18. When GerdQ ≥8, the patients could be symptom based diagnosed as GERD. GerdQ was consisted of 3 categories: A, B and C. Each category has two questions with sum of score ranging from 0 to 6. Symptom controlled was defined as patients with all items ≤1 in A and C category of GerdQ.

    Time frame: 16 weeks

07

Results

Posted Sep 28, 2012

Participant flow

Three hundred and five patients, out of the 311 patients who signed the informed consent, were randomized to receive 8 weeks (n=154) or 2 weeks (n=151) of esomeprazole treatment.

Treatment Period
Participant flow — Treatment Period
MilestoneEsomeprazole 8 Weeks TreatmentEsomeprazole 2 Weeks Treatment
Started154151
Completed136126
Not completed1825
Withdrew: Lack of efficacy1825
Follow-up
Participant flow — Follow-up
MilestoneEsomeprazole 8 Weeks TreatmentEsomeprazole 2 Weeks Treatment
Started136124
Completed135122
Not completed12

Outcome measures

PrimarySymptom Control Rate at 24 Weeks Assessed by Gerd Q Questionnaire.

GerdQ Scores ranging from 0 to 3 were applied for the positive predictors and from 3 to 0 (reversed order, where 3 = none) for negative predictors. The GerdQ score was calculated as the sum of these scores, giving a total score ranging from 0 to 18. When GerdQ ≥8, the patients could be symptom based diagnosed as GERD. GerdQ was consisted of 3 categories: A, B and C. Each category has two questions with sum of score ranging from 0 to 6. Symptom controlled was defined as patients with all items ≤1 in A and C category of GerdQ.

Time frame:
24 weeks
Reported as:
Number · percentage of participants
Symptom Control Rate at 24 Weeks Assessed by Gerd Q Questionnaire.
percentage of participantsEsomeprazole 8 Weeks TreatmentEsomeprazole 2 Weeks Treatment
Symptom Control Rate at 24 Weeks Assessed by Gerd Q Questionnaire.94.987.3
SecondaryThe Success Rate in Whole Study Duration.

Success is defined as patients with symptom relief after 8 weeks or 2 weeks esomeprazole treatment, and also get symptom controlled during maintenance treatment / follow-up period.

Time frame:
24 weeks after end of treatment
Reported as:
Number · percentage of participants
The Success Rate in Whole Study Duration.
percentage of participantsEsomeprazole 8 Weeks TreatmentEsomeprazole 2 Weeks Treatment
The Success Rate in Whole Study Duration.83.872.8
SecondaryTime to First Relapse.

Time to first relapse is from the last dose during the treatment period to date of first time patient comes to the investigator due to symptom recure and need for treatment. Time to first relapse is actually the time when 50% of patients had relapse. Up to the end of study, there were less than 50% of the patients in arm esomeprazole 2 weeks group had relapse so was unable to compute this endpoint

Time frame:
From baseline to 24 weeks after end of treatment
Reported as:
Median · days
Time to First Relapse.
daysEsomeprazole 8 Weeks TreatmentEsomeprazole 2 Weeks Treatment
Time to First Relapse.NA (35 to NA)57 (12 to 174)
SecondarySymptom Relief Rate in 2 Treatment Regimens.

Symptom relief is defined as no more than 1 day of mild symptoms of GERD during previous 7 days after 8 weeks or 2 weeks of treatment.

Time frame:
8 weeks for arm 1, 2 weeks for arm 2
Reported as:
Number · percentage of participans
Symptom Relief Rate in 2 Treatment Regimens.
percentage of participansEsomeprazole 8 Weeks TreatmentEsomeprazole 2 Weeks Treatment
Symptom Relief Rate in 2 Treatment Regimens.88.383.4
SecondarySymptom Relief Rate After 2 Weeks and 8 Weeks in 8 Weeks Treatment Group.

Symptom relief is defined as no more than 1 day of mild symptoms of GERD during previous 7 days after 8 weeks or 2 weeks of treatment.

Time frame:
2 and 8 weeks
Reported as:
Number · percentage of participants
Symptom Relief Rate After 2 Weeks and 8 Weeks in 8 Weeks Treatment Group.
percentage of participantsEsomeprazole 8 Weeks TreatmentEsomeprazole 2 Weeks Treatment
2 weeks54.5—
8 weeks88.3—
SecondaryNumber of Patients With Unscheduled Hospital Visit(s)
Time frame:
from baseline to week 24 after end of treatment
Reported as:
Number · participants
Number of Patients With Unscheduled Hospital Visit(s)
participantsEsomeprazole 8 Weeks TreatmentEsomeprazole 2 Weeks Treatment
Number of Patients With Unscheduled Hospital Visit(s)5980
SecondaryPercentage of Patients Satisfaction

Satisfied - satisfaction score of 1-4 while very satisfied - satisfaction score of 1-2.

Time frame:
24 weeks after end of treatment
Reported as:
Number · percentage of participants
Percentage of Patients Satisfaction
percentage of participantsEsomeprazole 8 Weeks TreatmentEsomeprazole 2 Weeks Treatment
Satisfied10096
Very satisfied48.524.6
SecondarySymptom Control Rate at 8 Weeks Assessed by Gerd Q Questionnaire

GerdQ Scores ranging from 0 to 3 were applied for the positive predictors and from 3 to 0 (reversed order, where 3 = none) for negative predictors. The GerdQ score was calculated as the sum of these scores, giving a total score ranging from 0 to 18. When GerdQ ≥8, the patients could be symptom based diagnosed as GERD. GerdQ was consisted of 3 categories: A, B and C. Each category has two questions with sum of score ranging from 0 to 6. Symptom controlled was defined as patients with all items ≤1 in A and C category of GerdQ.

Time frame:
8 weeks
Reported as:
Number · percentage of participants
Symptom Control Rate at 8 Weeks Assessed by Gerd Q Questionnaire
percentage of participantsEsomeprazole 8 Weeks TreatmentEsomeprazole 2 Weeks Treatment
Symptom Control Rate at 8 Weeks Assessed by Gerd Q Questionnaire80.175.4
SecondarySymptom Control Rate at 16 Weeks Assessed by Gerd Q Questionnaire

GerdQ Scores ranging from 0 to 3 were applied for the positive predictors and from 3 to 0 (reversed order, where 3 = none) for negative predictors. The GerdQ score was calculated as the sum of these scores, giving a total score ranging from 0 to 18. When GerdQ ≥8, the patients could be symptom based diagnosed as GERD. GerdQ was consisted of 3 categories: A, B and C. Each category has two questions with sum of score ranging from 0 to 6. Symptom controlled was defined as patients with all items ≤1 in A and C category of GerdQ.

Time frame:
16 weeks
Reported as:
Number · percentage of participants
Symptom Control Rate at 16 Weeks Assessed by Gerd Q Questionnaire
percentage of participantsEsomeprazole 8 Weeks TreatmentEsomeprazole 2 Weeks Treatment
Symptom Control Rate at 16 Weeks Assessed by Gerd Q Questionnaire85.380.2

Adverse events

Collected over From baseline to 24 weeks after treatment.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Esomeprazole 8 Weeks Treatment—0/154 (0%)0/154 (0%)
Esomeprazole 2 Weeks Treatment—0/151 (0%)0/151 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Esomeprazole 8 Weeks TreatmentEsomeprazole 2 Weeks TreatmentTotal
<=18 years000
Between 18 and 65 years143140283
>=65 years111122
Age Continuous
Age Continuous(years)Esomeprazole 8 Weeks TreatmentEsomeprazole 2 Weeks TreatmentTotal
Mean45.9 ± 12.7244.9 ± 13.1245.4 ± 12.91
Sex: Female, Male
Sex: Female, Male(Participants)Esomeprazole 8 Weeks TreatmentEsomeprazole 2 Weeks TreatmentTotal
Female8054134
Male7497171
Region of Enrollment
Region of Enrollment(participants)Esomeprazole 8 Weeks TreatmentEsomeprazole 2 Weeks TreatmentTotal
China154151305
08

Study locations

8 sites
  • Research Site
    Guangzhou, Guangdong, China
  • Research Site
    Wuhan, Hubei, China
  • Research Site
    Nanjing, Jiangsu, China
  • Research Site
    Jinan, Shandong, China
  • Research Site
    Xian, Shanxi, China
  • Research Site
    Hangzhou, Zhejiang, China
  • Research Site
    Beijin, China
  • Research Site
    Shanghai, China
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2010, a primary completion of Jun 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2012, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2010
First posted
May 10, 2010
Start
Apr 2010
Primary completionActual
Jun 2011
CompletionActual
Jun 2011
Results first posted
Sep 28, 2012
Last update
Sep 28, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01119768
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 10, 2010
Start date
Apr 2010
Primary completion
Jun 2011
Completion
Jun 2011
Results posted
Sep 28, 2012
Last update
Sep 28, 2012

Study contacts

Wenyu Guo
study director · AstraZeneca China MC
Prof. Yuan Yaozong
principal investigator · Shanghai Jiaotong University, School of Medicine, Affiliated of Ruijin Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esomeprazole

Start the discussion